2Cleator S,Heller W,Coombes RC.Triple-negative breast cancer:therapeutic options[J].Lancet Oncol,2007,8:235-244.
3Vona-Davis L,Rose DP,Hazard H,et al.Triple-negative breast cancer and obesity in a rural Appalachian population.Cancer Epidemiol[J].Biomarkers Prev,2008,17:3319-3324.
4Nielsen TO,Hsu FD,Jensen K,et al.Immunohistoehemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J].Clin Cancer Bes,2004,10:5367-5374.
5Korsehing E,Packeisen J,Agelopoulos K,et al.Cytogenetic alterations and cytokeratin expression patterns in breast cancer:integrating a new model of breast differentiation into cytogenetie pathways of breast carcinogenesis[J].Lab Invest,2002,82:1525-1533.
9Osaki M,Oshimura M,lto H.PDK-Akt pathway:its functions and alterations in human cancer[J].Apoptasis,2004,9:667-676.
10Edwards LA,Thiessen B,Draguwska WH,et al.Inhibition of ILK in PTEN-mumnt human glioblastomas inhibits PKB/Akt aetiva-tion.induces apoptosis,and delays tunlor growth[J].Oncogene,2005,24:3596-3605.
2Qiu J,Xue X,Hu C. Comparison of clinicopathological features and prognosis in triple-negative and non-triple negative breast cancer [J]. J Cancer,2016,7(2) : 167-173.
4Qi jP, Yang YL, Zhu H, et al. Expression of the androgen receptor and its correlation with molecuar subtypes in 980 chinese breast cancer patients [J]. Breast Cancer, 2012,10(6) : 1-8.
